FDA CRL - Dr. Reddy'S Laboratories

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Dr. Reddy’s Laboratories SA regarding its Biologics License Application (BLA 761376). The agency determined that the application could not be approved in its current form due to several outstanding issues.

A primary concern stems from a pre-license inspection, where objectionable conditions were identified. Resolution of these conditions, requiring the facility to demonstrate compliance with current Good Manufacturing Practices (cGMP), is mandatory and may necessitate a re-inspection before the BLA can be approved.

Beyond facility issues, the FDA requires comprehensive updates and additional information. This includes a detailed safety update, presenting new clinical study data, updated exposure information, and a summary of worldwide product safety experience, including immunogenicity and foreign labeling. Other comments involve the proposed proprietary name, which was conditionally acceptable, and various aspects of product quality, prescribing information, and carton/container labeling that will need to be reviewed once other deficiencies are addressed.

Dr. Reddy's Laboratories SA is required to fully address all identified deficiencies and resubmit the BLA within one year. The product cannot be legally marketed until the application receives FDA approval.